CSPC Pharmaceutical

CSPC Pharmaceutical CSPCY Stock

$3.97   0.000000%
Add to favorites
Market Cap
$11.32B
LOW - HIGH [24H]
$3.93 - $3.96
VOLUME [24H]
$16.00K
P/E Ratio
10.72
Earnings per share
$0.37
ISIN
US12591J2078
Price   Prediction

CSPC Pharmaceutical Price Chart

Sorry, that's all we've gotfor now...

CSPC Pharmaceutical (CSPCY) stock price today is 3.97 USD on OTC Markets OTCPK (0% on the day). Updated .

CSPC Pharmaceutical CSPCY Financial and Trading Overview

CSPC Pharmaceutical stock price 3.97 USD
Previous Close 4 USD
Open 4 USD
Bid 3.94 USD x 400000
Ask 4.29 USD x 430000
Day's Range 4 - 4 USD
52 Week Range 3.26 - 5.46 USD
Volume 350 USD
Avg. Volume 1.15K USD
Market Cap 11.32B USD
Beta (5Y Monthly) 0.773
PE Ratio (TTM) 10.72973
EPS (TTM) 0.37 USD
Forward Dividend & Yield 0.17 (4.24%)
Ex-Dividend Date October 21, 2026
1y Target Est N/A

CSPCY Valuation Measures

Enterprise Value -4685915648 USD
Trailing P/E 10.72973
Forward P/E N/A
PEG Ratio (5 yr expected) 0.94
Price/Sales (ttm) 0.36079556
Price/Book (mrq) 2.0091274
Enterprise Value/Revenue -0.149
Enterprise Value/EBITDA -0.467

Trading Information

CSPC Pharmaceutical Stock Price History

Beta (5Y Monthly) 0.773
52-Week Change 2.84%
S&P500 52-Week Change 12.00%
52 Week High 5.46 USD
52 Week Low 3.26 USD
50-Day Moving Average 4.47 USD
200-Day Moving Average 4.38 USD

CSPCY Share Statistics

Avg. Volume (3 month) 1.15K USD
Avg. Daily Volume (10-Days) 470 USD
Shares Outstanding 2.85B
Float 1.9B
Short Ratio N/A
% Held by Insiders 0%
% Held by Institutions 0%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0.286
Trailing Annual Dividend Yield 7.14%
5 Year Average Dividend Yield 308.00%
Payout Ratio 0.4038
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 23.73%
Operating Margin (ttm) 28.14%
Gross Margin 72.05%
EBITDA Margin 31.96%

Management Effectiveness

Return on Assets (ttm) N/A
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 31.37B USD
Revenue Per Share (ttm) 11.02 USD
Quarterly Revenue Growth (yoy) 0.70%
Gross Profit (ttm) 22.61B USD
EBITDA 10.03B USD
Net Income Avi to Common (ttm) 7.45B USD
Diluted EPS (ttm) 0.37
Quarterly Earnings Growth (yoy) 1.89%

Balance Sheet

Total Cash (mrq) 18.42B USD
Total Cash Per Share (mrq) 6.49 USD
Total Debt (mrq) 652.49M USD
Total Debt/Equity (mrq) 1.66 USD
Current Ratio (mrq) N/A
Book Value Per Share (mrq) 1.9759822

Cash Flow Statement

Operating Cash Flow (ttm) N/A
Levered Free Cash Flow (ttm) N/A

Profile of CSPC Pharmaceutical

Country United States
State N/A
City Shijiazhuang
Address No.896 Zhongshandong Street
ZIP 050035
Phone 86 311 8703 7015
Website https://www.cspc.com.hk
Industry Drug Manufacturers - General
Sector(s) Healthcare
Full Time Employees 19700

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Q&A For CSPC Pharmaceutical Stock

What is a current CSPCY stock price?

CSPC Pharmaceutical CSPCY stock price today per share is 3.97 USD.

How to purchase CSPC Pharmaceutical stock?

You can buy CSPCY shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for CSPC Pharmaceutical?

The stock symbol or ticker of CSPC Pharmaceutical is CSPCY.

Which industry does the CSPC Pharmaceutical company belong to?

The CSPC Pharmaceutical industry is Drug Manufacturers - General.

How many shares does CSPC Pharmaceutical have in circulation?

The max supply of CSPC Pharmaceutical shares is 2.85B.

What is CSPC Pharmaceutical Price to Earnings Ratio (PE Ratio)?

CSPC Pharmaceutical PE Ratio is 10.72973000 now.

What was CSPC Pharmaceutical earnings per share over the trailing 12 months (TTM)?

CSPC Pharmaceutical EPS is 0.37 USD over the trailing 12 months.

Which sector does the CSPC Pharmaceutical company belong to?

The CSPC Pharmaceutical sector is Healthcare.

$2.02T
Total marketcap
$115.18B
Total volume
BTC 57.76%   •   ETH 9.63%
Dominance
Select currency